加拿大胃肠病学会胆汁酸性腹泻管理临床实践指南
该指南由加拿大胃肠病学会制定,基于系统检索和GRADE方法,针对慢性腹泻患者中胆汁酸性腹泻(BAD)的评估与管理提出推荐。证据确定性普遍很低,17条推荐中16条为条件性推荐。建议对慢性腹泻患者考虑危险因素并检测BAD,初治疗首选考来烯胺,维持治疗用最低有效剂量。
要点
- 慢性腹泻患者应评估BAD危险因素:回肠末端切除、胆囊切除或腹部放疗。
- 对腹泻型肠易激综合征、功能性腹泻及无炎症的克罗恩病患者建议检测BAD。
- BAD初治疗建议考来烯胺,耐受性差时换用其他胆汁酸螯合剂。
核心结论
- 基于系统评价,慢性腹泻患者应考虑胆汁酸性腹泻(BAD)。
- 对BAD检测阳性的患者,建议试用胆汁酸螯合剂(BAST),初始选用考来烯胺。
研究设计与样本
- 制定机构为加拿大胃肠病学会,采用系统检索和GRADE方法评估证据质量与推荐强度。
- 通过迭代过程形成患者人群、干预、对照和结局问题,并由专家组投票。
主要发现
- 证据确定性普遍评为极低,17条推荐中16条为条件性推荐。
- 建议通过危险因素(回肠末端切除、胆囊切除或腹部放疗)而非附加症状来识别可能的BAD患者。
- 建议检测(如可用)使用75硒同型胆酸牛磺酸或7α-羟基-4-胆甾烯-3-酮,检测对象包括腹泻型肠易激综合征、功能性腹泻及无炎症的克罗恩病患者。
- 建议检测优于经验性胆汁酸螯合剂治疗(BAST)。
- 建议考来烯胺作为初始治疗,耐受性有问题时换用替代BAST。
关键数值与推荐
- 慢性腹泻影响约5%的总人口。
- 17条推荐中16条为条件性推荐,证据确定性普遍极低。
- 建议对广泛回肠克罗恩病或切除的患者反对使用BAST,若BAST不耐受建议改用替代止泻药。
- 维持BAST应以最低有效剂量给药,可尝试间歇按需给药,同时审查合并用药。
- 对BAST治疗后症状持续的患者应重新检查。
临床怎么用
- 对慢性腹泻患者,应询问回肠末端切除、胆囊切除或腹部放疗史以评估BAD风险。
- 对腹泻型肠易激综合征、功能性腹泻及无炎症的克罗恩病患者,建议检测BAD而非经验性治疗。
- BAD检测阳性者初始选用考来烯胺,耐受性差时换用其他BAST。
- 广泛回肠克罗恩病或切除患者避免BAST,不耐受时改用其他止泻药。
- 维持治疗用最低有效剂量,可尝试间歇按需给药,并定期审查合并用药和重新评估。
局限性
- 证据确定性普遍评为极低,多数推荐为条件性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Chronic diarrhea affects about 5% of the population overall. Altered bile acid metabolism is a common but frequently undiagnosed cause. METHODS: We performed a systematic search of publication databases for studies of assessment and management of bile acid diarrhea (BAD). The certainty (quality) of evidence and strength of recommendations were rated according to the Grading of Recommendation Assessment, Development and Evaluation approach. Patient population, intervention, comparator, and outcome questions were developed through an iterative process and were voted on by a group of specialists. RESULTS: The certainty of evidence was generally rated as very low. Therefore, 16 of 17 recommendations are conditional. In patients with chronic diarrhea, consideration of risk factors (terminal ileal resection, cholecystectomy, or abdominal radiotherapy), but not additional symptoms, was recommended for identification of patients with possible BAD. The group suggested testing using 75selenium homocholic acid taurine (where available) or 7α-hydroxy-4-cholesten-3-one, including patients with irritable bowel syndrome with diarrhea, functional diarrhea, and Crohn's disease without inflammation. Testing was suggested over empiric bile acid sequestrant therapy (BAST). Once remediable causes are managed, the group suggested cholestyramine as initial therapy, with alternate BAST when tolerability is an issue. The group suggested against BAST for patients with extensive ileal Crohn's disease or resection and suggested alternative antidiarrheal agents if BAST is not tolerated. Maintenance BAST should be given at the lowest effective dose, with a trial of intermittent, on-demand administration, concurrent medication review, and reinvestigation for patients whose symptoms persist despite BAST. CONCLUSIONS: Based on a systematic review, BAD should be considered for patients with chronic diarrhea. For patients with positive results from tests for BAD, a trial of BAST, initially with cholestyramine, is suggested.
引用
- Sadowski DC, Camilleri M, Chey WD, et al. Canadian Association of Gastroenterology Clinical Practice Guideline on the Management of Bile Acid Diarrhea. Clin Gastroenterol Hepatol. 2019. PMID: 31526844. doi:10.1016/j.cgh.2019.08.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。